AIMS: Our aim was to evaluate the activity, toxicity, and feasibility of electrochemotherapy (ECT) in patients with soft-tissue sarcomas (STS). METHODS: A two-stage phase II trial was conducted between October 2006 and March 2012. Patients (N = 34) with locally advanced or metastatic STS, unsuitable for standard oncological treatments and with maximum 3-cm deep tumors, received an intravenous bolus of bleomycin (15,000 IU/m(2)), followed by tumor electroporation according to the European Standard Operating Procedures of ECT. Outcome measures included local response according to response evaluation criteria in solid tumors (RECIST), toxicity and tumor control. Feasibility measures included the accuracy of electrode placement and the intensity of electric current flowing in tumor tissue. RESULTS: Median tumor size was 4.0 cm (range 2-12). Objective response, assessed on 71 target lesions, was 92.2 % (complete 32.3, 95 % CI 28-64). A total of 15 patients received up to four cycles due to incomplete response, but re-treatment did not significantly improve outcome (p = 0.205). After a median follow-up of 19.3 months, 2-year local control rate was 72.5 %. Median time to local failure (N = 11 patients) was 5.1 months. Tumor response (p = 0.041) and control (p = 0.047) correlated with histological grading. Relevant toxicity consisted of G3 skin ulceration and soft tissue necrosis (35 and 23 % of patients, respectively), although this was manageable on an outpatient basis. The accuracy of electrode placement was 47.1 %, and the adequacy of electroporative current 85.3 %. CONCLUSIONS: ECT may represent an active and safe treatment to achieve local control in advanced STS patients with symptomatic disease. Future research challenges include the improvement of electrode placement and voltage delivery together with the containment of soft tissue toxicity.
AIMS: Our aim was to evaluate the activity, toxicity, and feasibility of electrochemotherapy (ECT) in patients with soft-tissue sarcomas (STS). METHODS: A two-stage phase II trial was conducted between October 2006 and March 2012. Patients (N = 34) with locally advanced or metastatic STS, unsuitable for standard oncological treatments and with maximum 3-cm deep tumors, received an intravenous bolus of bleomycin (15,000 IU/m(2)), followed by tumor electroporation according to the European Standard Operating Procedures of ECT. Outcome measures included local response according to response evaluation criteria in solid tumors (RECIST), toxicity and tumor control. Feasibility measures included the accuracy of electrode placement and the intensity of electric current flowing in tumor tissue. RESULTS: Median tumor size was 4.0 cm (range 2-12). Objective response, assessed on 71 target lesions, was 92.2 % (complete 32.3, 95 % CI 28-64). A total of 15 patients received up to four cycles due to incomplete response, but re-treatment did not significantly improve outcome (p = 0.205). After a median follow-up of 19.3 months, 2-year local control rate was 72.5 %. Median time to local failure (N = 11 patients) was 5.1 months. Tumor response (p = 0.041) and control (p = 0.047) correlated with histological grading. Relevant toxicity consisted of G3 skin ulceration and soft tissue necrosis (35 and 23 % of patients, respectively), although this was manageable on an outpatient basis. The accuracy of electrode placement was 47.1 %, and the adequacy of electroporative current 85.3 %. CONCLUSIONS: ECT may represent an active and safe treatment to achieve local control in advanced STS patients with symptomatic disease. Future research challenges include the improvement of electrode placement and voltage delivery together with the containment of soft tissue toxicity.
Authors: Christopher M Byrne; John F Thompson; Heather Johnston; Peter Hersey; Michael J Quinn; T Michael Hughes; William H McCarthy Journal: Melanoma Res Date: 2005-02 Impact factor: 3.599
Authors: S Sleijfer; T Gorlia; C Lamers; H Burger; J-Y Blay; A Le Cesne; M Scurr; F Collin; L Pandite; S Marreaud; P Hohenberger Journal: Br J Cancer Date: 2012-07-17 Impact factor: 7.640
Authors: L M Mir; P Devauchelle; F Quintin-Colonna; F Delisle; S Doliger; D Fradelizi; J Belehradek; S Orlowski Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: Barbara Mali; Damijan Miklavcic; Luca G Campana; Maja Cemazar; Gregor Sersa; Marko Snoj; Tomaz Jarm Journal: Radiol Oncol Date: 2013-02-01 Impact factor: 2.991
Authors: G Sersa; T Jarm; T Kotnik; A Coer; M Podkrajsek; M Sentjurc; D Miklavcic; M Kadivec; S Kranjc; A Secerov; M Cemazar Journal: Br J Cancer Date: 2008-01-08 Impact factor: 7.640
Authors: Edoardo Crimini; Michela Roberto; Valter Degli Effetti; Paolo Marchetti; Andrea Botticelli; Francesca Matilde Schipilliti; Giulia Arrivi; Federica Mazzuca Journal: Case Rep Oncol Med Date: 2019-03-28
Authors: A L Tosi; L G Campana; F Dughiero; M Forzan; M Rastrelli; E Sieni; C R Rossi Journal: Med Biol Eng Comput Date: 2016-10-01 Impact factor: 2.602
Authors: L G Campana; M Cesari; F Dughiero; M Forzan; M Rastrelli; C R Rossi; E Sieni; A L Tosi Journal: Med Biol Eng Comput Date: 2015-09-01 Impact factor: 2.602
Authors: Luca G Campana; A James P Clover; Sara Valpione; Pietro Quaglino; Julie Gehl; Christian Kunte; Marko Snoj; Maja Cemazar; Carlo R Rossi; Damijan Miklavcic; Gregor Sersa Journal: Radiol Oncol Date: 2016-02-16 Impact factor: 2.991
Authors: Luca Giovanni Campana; Marco Bullo; Paolo Di Barba; Fabrizio Dughiero; Michele Forzan; Maria Evelina Mognaschi; Paolo Sgarbossa; Anna Lisa Tosi; Alessia Bernardis; Elisabetta Sieni Journal: Technol Cancer Res Treat Date: 2018-01-01